Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4649-4667
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Table 1 The 20 upregulated genes that displayed the greatest changes in their expression in anoctamin 5-depleted NUGC4 cells
Gene symbol | Gene name | Gene ID | Fold change |
PLCXD1 | Phosphatidylinositol-specific phospholipase C X domain containing 1 | TC0X00006433.hg.1 | 31.97 |
NDRG4 | NDRG family member 4 | TC1600008034.hg.1 | 29.88 |
CYP3A5 | Cytochrome P450 family 3 subfamily A member 5 | TC0700011953.hg.1 | 24.81 |
PLCXD1 | Phosphatidylinositol-specific phospholipase C X domain containing 1 | TC0Y00006433.hg.1 | 23.44 |
REG4 | Regenerating family member 4 | TC0100015477.hg.1 | 19.70 |
CIDEB | Cell death-inducing DFFA-like effector b | TC1400008752.hg.1 | 17.86 |
DHRS9 | Dehydrogenase/reductase 9 | TC0200009905.hg.1 | 17.02 |
CIDEC | Cell death-inducing DFFA-like effector c | TC0300010217.hg.1 | 16.73 |
SPRR1A | Small proline rich protein 1A | TC0100010017.hg.1 | 16.66 |
APOD | Apolipoprotein D | TC0300013645.hg.1 | 16.57 |
SEMA7A | Semaphorin 7A | TC1500010018.hg.1 | 16.09 |
C11orf86 | Chromosome 11 open reading frame 86 | TC1100008109.hg.1 | 15.57 |
BNIPL | BCL2 interacting protein like | TC0100009936.hg.1 | 15.52 |
SUSD2 | Sushi domain containing 2 | TC2200006883.hg.1 | 15.25 |
MAPRE3 | Microtubule-associated protein RP/EB family member 3 | TC0200007048.hg.1 | 14.99 |
CYP1A1 | Cytochrome P450 family 1 subfamily A member 1 | TC1500010042.hg.1 | 14.69 |
GOLT1A | Golgi transport 1A | TC0100017022.hg.1 | 13.79 |
CNN2 | Calponin 2 | TC1900006507.hg.1 | 13.74 |
ANTXR2 | ANTXR cell adhesion molecule 2 | TC0400011144.hg.1 | 13.54 |
APOBEC1 | Apolipoprotein B mRNA editing enzyme catalytic subunit 1 | TC1200009789.hg.1 | 12.19 |
Table 2 The 20 downregulated genes that displayed the greatest changes in their expression in anoctamin 5-depleted NUGC4 cells
Gene symbol | Gene name | Gene ID | Fold change |
CDK2 | Cyclin-dependent kinase 2 | TC1200007819.hg.1 | -53.84 |
DTL | Denticleless E3 ubiquitin ligase homolog | TC0100011512.hg.1 | -27.60 |
RABL3 | RAB, member of RAS oncogene family like 3 | TC0300012157.hg.1 | -20.16 |
CKS1B | CDC28 protein kinase regulatory submit 1B | TC0100010100.hg.1 | -19.34 |
LMNB1 | Lamin B1 | TC0500008544.hg.1 | -19.18 |
IFRD2 | Interferon-related developmental regulator 2 | TC0300013981.hg.1 | -18.61 |
PLK1 | Polo like kinase 1 | TC1600007235.hg.1 | -17.89 |
GINS1 | GINS complex subunit 1 | TC2000007016.hg.1 | -17.87 |
CDK6 | Cyclin-dependent kinase 6 | TC0700011785.hg.1 | -17.08 |
XRCC2 | X-ray repair cross complementing 2 | TC0700013119.hg.1 | -14.77 |
POGLUT3 | Protein O-glucosyltransferase 3 | TC1100012229.hg.1 | -14.47 |
DSG2 | Desmoglein 2 | TC1800007014.hg.1 | -14.37 |
NEMP1 | Nuclear envelope integral membrane protein 1 | TC1200010946.hg.1 | -14.31 |
CBX5 | Chromobox 5 | TC1200010833.hg.1 | -14.20 |
ANKRD52 | Ankyrin repeat domain 52 | TC1200010902.hg.1 | -14.20 |
ITGB1 | Integrin subunit beta 1 | TC1000010265.hg.1 | -14.16 |
H2BC14 | H2B clustered histone 14 | TC0600007377.hg.1 | -13.25 |
SCAMP2 | Secretory carrier membrane protein 2 | TC1500010047.hg.1 | -13.05 |
CMTM7 | CKLF like MARVEL transmembrane domain containing 7 | TC0300006968.hg.1 | -13.02 |
GINS4 | GINS complex subunit 4 | TC0800007416.hg.1 | -12.66 |
Table 3 Ingenuity pathway analysis of anoctamin 5-depleted NUGC4 cells
Category | Name | Molecules | P value (range) |
Disease and Disorders | Cancer | 3136 | 1.54 × 10-3–2.23 × 10-15 |
Neurological Disease | 76 | 1.27 × 10-3–2.23 × 10-15 | |
Organismal Injury and Abnormalities | 3147 | 1.54 × 10-3–2.23 × 10-15 | |
Cardiovascular Disease | 138 | 1.43 × 10-3–4.07 × 10-14 | |
Reproductive System Disease | 1942 | 1.54 × 10-3–1.09 × 10-10 | |
Molecular and Cellular Functions | DNA Replication, Recombination, and Repair | 460 | 1.54 × 10-3–9.69 × 10-22 |
Cell Cycle | 650 | 1.54 × 10-3–1.98 × 10-20 | |
Cellular Assembly and Organization | 533 | 1.57 × 10-3–9.22 × 10-16 | |
Cellular Development | 691 | 1.59 × 10-3–2.66 × 10-14 | |
Cellular Growth and Proliferation | 677 | 1.40 × 10-3–2.66 × 10-14 | |
Physiological System Development and Function | Connective Tissue Development and Function | 60 | 1.14 × 10-3–8.83 × 10-6 |
Tissue Development | 164 | 1.57 × 10-3–1.11 × 10-4 | |
Embryonic Development | 80 | 1.21 × 10-3–2.07 × 10-4 | |
Hair and Skin Development and Function | 55 | 6.37 × 10-4–2.07 × 10-4 | |
Organ Development | 69 | 6.37 × 10-4–2.07 × 10-4 |
Table 4 Five-year overall survival rates with cut-off values for anoctamin 5 expression scores
Table 5 Relationships between clinicopathological factors of gastric cancer patients and anoctamin 5 expression
Variables | N | IHC score | P value | ||
High group ( 1.3) | Low group (< 1.3) | ||||
Total | 195 | 58 | 137 | ||
Sex | Male | 128 | 35 | 93 | 0.3262 |
Female | 67 | 23 | 44 | ||
Age | < 65 | 77 | 25 | 52 | 0.5246 |
65 | 118 | 33 | 85 | ||
Tumor location | U | 41 | 15 | 26 | 0.3367 |
M, L | 154 | 43 | 111 | ||
Tumor length (mm) | < 30 | 63 | 22 | 41 | 0.3158 |
30 | 132 | 36 | 96 | ||
Histological type | tub1, tub2, pap | 96 | 35 | 61 | 0.0596 |
por, sig, muc | 99 | 23 | 76 | ||
Lymphatic invasion | Negative | 110 | 34 | 76 | 0.7529 |
Positive | 85 | 24 | 61 | ||
Venous invasion | Negative | 131 | 38 | 93 | 0.7419 |
Positive | 64 | 20 | 44 | ||
pT | pT1-2 | 137 | 37 | 100 | 0.2312 |
pT3-4 | 58 | 21 | 37 | ||
pN | pN0 | 139 | 40 | 99 | 0.7294 |
pN1-3 | 56 | 18 | 38 |
Table 6 Univariate and multivariate analyses of prognostic factors associated with 5-year overall survival
Variables | N | Univariate | Multivariate | ||
5-yr OS rate (%) | P value | HR (95%CI) | P value | ||
Total | 195 | ||||
Sex | |||||
Male | 128 | 87.9 | 0.3274 | ||
Female | 67 | 85.3 | |||
Age | |||||
< 65 | 77 | 89.7 | 0.4113 | ||
65 | 118 | 85.2 | |||
Location | |||||
U | 41 | 80.9 | 0.2629 | ||
M, L | 154 | 88.6 | |||
Tumor length (mm) | |||||
< 30 | 63 | 97.8 | 0.0020a | 3.010 (0.347-26.12) | 0.3176 |
30 | 132 | 80.1 | |||
Histological type | |||||
tub1, tub2, pap | 96 | 88.3 | 0.4544 | ||
por, sig, muc | 99 | 85.6 | |||
Lymphatic invasion | |||||
Negative | 110 | 96.1 | 0.0002a | 1.872 (0.549-6.384) | 0.3166 |
Positive | 85 | 75.7 | |||
Venous invasion | |||||
Negative | 131 | 90.6 | 0.0126a | 1.085 (0.476-2.472) | 0.8469 |
Positive | 64 | 79.3 | |||
pT | |||||
pT1-2 | 137 | 95.9 | < 0.0001a | 5.240 (1.807-15.20) | 0.0023c |
pT3-4 | 58 | 65.5 | |||
pN | |||||
pN0 | 139 | 94.1 | < 0.0001a | 2.148 (0.695-6.643) | 0.1844 |
pN1-3 | 56 | 67.6 | |||
IHC score | |||||
< 1.3 | 137 | 89.6 | 0.0104a | 2.318 (1.016-5.288) | 0.0457c |
1.3 | 58 | 73.9 |
- Citation: Fukami T, Shiozaki A, Kosuga T, Kudou M, Shimizu H, Ohashi T, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Morinaga Y, Konishi E, Otsuji E. Anoctamin 5 regulates the cell cycle and affects prognosis in gastric cancer. World J Gastroenterol 2022; 28(32): 4649-4667
- URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4649.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4649